The multidrug resistance of in vitro tumor cell lines derived from human breast carcinoma MCF-7 does not influence pentavalent technetium-99m-dimercaptosuccinic acid uptake

被引:6
作者
Denoyer, D [1 ]
Perek, N [1 ]
Le Jeune, N [1 ]
Frère, D [1 ]
Dubois, F [1 ]
机构
[1] Fac Med Jacques Lisfranc, Res Grp Cell Death & Neoplasia, Dept Biophys & Radiopharmaceut, St Etienne, France
关键词
multidrug resistance; glutathione; reversal agents; Tc-99m-(V)-DMSA; Tc-99m-MIBI; breast carcinoma cell lines;
D O I
10.1089/108497803770418337
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The main causes of multidrug resistance (MDR) are overexpression of P-glycoprotein (P-gp) and multidrug resistance-associated protein isoform I (MRP1) often associated with high levels of glutathione (GSH). We investigated whether MDR phenotype can influence Tc-99m-(V)-DMSA [pentavalent technetium-99m-dimercaptosuccinic acid] entry by comparing its uptake with that of Tc-99m-sestamibi (MIBI) on an in vitro model of sensitive (MCF-7) and variant resistant cell lines. Drug resistance was assessed by immunoblotting, GSH measurement, and 3-[4,5-dimethylthiazol-2-yl]-2,5, diphenyl tetrazolium bromide (MTT) assay. To correlate MDR phenotype with tracer accumulation, uptakes were performed with and without P-gp and MRP1 inhibitors and after GSH modulation. Similar accumulation of Tc-99m-(V)-DMSA was observed in all cell lines and the use of MDR reversals did not enhance its uptake. Our results demonstrate clearly that Tc-99m-(V)-DMSA uptake is not related to either P-gp and MRP1 expression, or GSH levels. In contrast, Tc-99m-MIBI accumulation is inversely proportional to the cell MDR phenotype. The combination of Tc-99m-(V)-DMSA and Tc-99m-MIBI may be a useful tool for noninvasive detection of malignant sites and their chemoresistance status.
引用
收藏
页码:791 / 801
页数:11
相关论文
共 34 条
[1]   Determination of medullary thyroid carcinoma metastases by 201Tl, 99Tcm(V)DMSA, 99Tcm-MIBI and 99Tcm-tetrofosmin [J].
Adalet, I ;
Koçak, M ;
Oguz, H ;
Alagöl, F ;
Cantez, S .
NUCLEAR MEDICINE COMMUNICATIONS, 1999, 20 (04) :353-359
[2]  
Aszalos A, 1998, ANTICANCER RES, V18, P2937
[3]   TC-99(M)-SESTAMIBI AS AN AGENT FOR IMAGING P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE - IN-VITRO AND IN-VIVO STUDIES IN A RAT BREAST-TUMOR CELL-LINE AND ITS DOXORUBICIN-RESISTANT VARIANT [J].
BALLINGER, JR ;
HUA, HA ;
BERRY, BW ;
FIRBY, P ;
BOXEN, I .
NUCLEAR MEDICINE COMMUNICATIONS, 1995, 16 (04) :253-257
[4]   Multidrug resistance-associated protein: A protein distinct from p-glycoprotein involved in cytotoxic drug expulsion [J].
Barrand, MA ;
Bagrij, T ;
Neo, SY .
GENERAL PHARMACOLOGY, 1997, 28 (05) :639-645
[5]   99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo [J].
Bernard, BF ;
Krenning, EP ;
Breeman, WAP ;
Ensing, G ;
Benjamins, H ;
Bakker, WH ;
Visser, TJ ;
de Jong, M .
NUCLEAR MEDICINE AND BIOLOGY, 1998, 25 (03) :233-240
[6]  
BLOWER PJ, 1991, J NUCL MED, V32, P845
[7]   OVEREXPRESSION OF A TRANSPORTER GENE IN A MULTIDRUG-RESISTANT HUMAN LUNG-CANCER CELL-LINE [J].
COLE, SPC ;
BHARDWAJ, G ;
GERLACH, JH ;
MACKIE, JE ;
GRANT, CE ;
ALMQUIST, KC ;
STEWART, AJ ;
KURZ, EU ;
DUNCAN, AMV ;
DEELEY, RG .
SCIENCE, 1992, 258 (5088) :1650-1654
[8]  
Cordobes MD, 1996, J NUCL MED, V37, P286
[9]   POTENTIATION OF ANTICANCER-DRUG CYTOTOXICITY BY MULTIDRUG-RESISTANCE CHEMOSENSITIZERS INVOLVES ALTERATIONS IN MEMBRANE FLUIDITY LEADING TO INCREASED MEMBRANE-PERMEABILITY [J].
DRORI, S ;
EYTAN, GD ;
ASSARAF, YG .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 228 (03) :1020-1029
[10]   Salidiuretic action by genistein in the isolated, perfused rat kidney [J].
Giménez, I ;
Martinez, RM ;
Lou, M ;
Mayoral, JA ;
Garay, RP ;
Alda, JO .
HYPERTENSION, 1998, 31 (02) :706-711